

# Levonorgestrel spiraal versus progesteron oraal voor de behandeling van hyperplasie zonder atypie van het endometrium.

Published: 07-01-2009

Last updated: 06-05-2024

Treatment of endometrial hyperplasia by an IUD that contains progesteron is more effective and has less side-effects than the treatment with progesteron oral.

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruitment stopped
<b>Health condition type</b>	Reproductive neoplasms female benign
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON36959

### Source

ToetsingOnline

### Brief title

HYPROLEV-study

### Condition

- Reproductive neoplasms female benign

### Synonym

abnormal endometrial tissue, precancer leasion of woomb

### Research involving

Human

### Sponsors and support

**Primary sponsor:** obstetrie en gynaecologie

**Source(s) of monetary or material Support:** Ministerie van OC&W

## Intervention

**Keyword:** endometrium, hyperplasia, levonorgestrel IUD, progesteron

## Outcome measures

### Primary outcome

endometrial atrophy after treatment

### Secondary outcome

less side-effects in the study-group than the control-group

## Study description

### Background summary

Endometrial hyperplasia without atypie is treated by oral progesteron. This treatment has some side-effects. Another way of treating this condition is by an IUD that contains progesteron. This method is already been investigated and is also effective. We think that this second option (the IUD which contains progesteron) is more effective and is also has less side-effects than the oral treatment. That is why we want to do this randomized controlled trial. For this study we need to include 90 patients.

### Study objective

Treatment of endometrial hyperplasia by an IUD that contains progesteron is more effective and has less side-effects than the treatment with progesteron oral.

### Study design

prospective randomized clinical trial

### Intervention

One group will be treated by oral progesteron and the other group will get a levonorgestrel-IUD.

### Study burden and risks

Patients are four times asked to fill in a form which will take about 10-15 minutes each time.

There are no risks for the patient in this study.

## Contacts

### **Public**

Selecteer

Debyelaan 25  
6202 AZ Maastricht  
Nederland

### **Scientific**

Selecteer

Debyelaan 25  
6202 AZ Maastricht  
Nederland

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### **Age**

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

endometrial hyperplasia (simple and complex), Dutch language

### Exclusion criteria

endometrial cancer, hyperplasia with atypie, history of hyperplasia, contra-indication for treatment with progesteron, biops not possible for any reason

## Study design

### Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Open (masking not used)
Control:	Active
Primary purpose:	Treatment

### Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	11-04-2011
Enrollment:	90
Type:	Actual

### Medical products/devices used

Product type:	Medicine
Brand name:	Mirena
Generic name:	Levonorgestrel IUD
Registration:	Yes - NL outside intended use
Product type:	Medicine
Brand name:	provera
Generic name:	medroxyprogesteron
Registration:	Yes - NL intended use

## Ethics review

Approved WMO

Date:	07-01-2009
Application type:	First submission
Review commission:	METC academisch ziekenhuis Maastricht/Universiteit Maastricht, METC azM/UM (Maastricht)
Approved WMO	
Date:	21-07-2009
Application type:	First submission
Review commission:	METC academisch ziekenhuis Maastricht/Universiteit Maastricht, METC azM/UM (Maastricht)
Approved WMO	
Date:	23-06-2010
Application type:	Amendment
Review commission:	METC academisch ziekenhuis Maastricht/Universiteit Maastricht, METC azM/UM (Maastricht)
Approved WMO	
Date:	09-02-2011
Application type:	Amendment
Review commission:	METC academisch ziekenhuis Maastricht/Universiteit Maastricht, METC azM/UM (Maastricht)
Approved WMO	
Date:	21-03-2011
Application type:	Amendment
Review commission:	METC academisch ziekenhuis Maastricht/Universiteit Maastricht, METC azM/UM (Maastricht)
Approved WMO	
Date:	26-04-2011
Application type:	Amendment
Review commission:	METC academisch ziekenhuis Maastricht/Universiteit Maastricht, METC azM/UM (Maastricht)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register	ID
EudraCT	EUCTR2008-006715-21-NL
CCMO	NL24978.068.08